Switching From Semaglutide to Tirzepatide: Timing and Doses
Switching from semaglutide to tirzepatide gets less help from the labels than most people expect. None of the four US labels has a switching section, and none converts one dose into the other. They do give each drug's dose steps and how long each stays in the body. They also warn against combining them. Three small published studies show how real clinics made the move.
The short version
- No conversion: the labels treat these as separate drugs with separate dose scales.
- No overlap: the Wegovy and Zepbound labels both advise against use with another GLP-1 drug.
- Approaches studied: one clinic restarted at the bottom step, one trial began one step up, and one clinic matched the start to the old dose.
This page covers the switch only. For how the two drugs compare in trials, see tirzepatide vs semaglutide. It gives no personal plan. A switch is a prescriber's call.
Sources: WEGOVY (semaglutide) injection and tablets, US prescribing information, Novo Nordisk, revised 06/2026, DailyMed; ZEPBOUND (tirzepatide) injection, US prescribing information, Eli Lilly, revised 08/2026, DailyMed; Kurinami N, Takada M and others, "Early Dose Escalation of Tirzepatide after Switching from Semaglutide in Type 2 Diabetes Mellitus." Endocrinology and Metabolism, 2025. PMC12765867, PMID 41088952; Jabbour S and others, prospective 12-week study of a direct switch from GLP-1 drugs to tirzepatide, Endocrine Practice, 2024. PMID 38723893; Barakat S, Ramdeen S and Khaimova R, "Safety and Efficacy of Switching Patients With Type 2 Diabetes From Glucagon-Like Peptide-1 Receptor Agonists to Tirzepatide: A Case Series." Hospital Pharmacy, 2024. PMC11497530, PMID 39449861
Why the milligrams do not match
Semaglutide acts on one gut hormone receptor, GLP-1. Tirzepatide acts on two, GLP-1 and GIP. Each is dosed on its own scale. So the same number on a pen means a different thing for each drug. The labels never compare them.
The closest thing to a conversion is a 2026 statistical model. It pooled 48 trial arms from people with type 2 diabetes. Then it asked which dose pairs gave similar average weight loss.
The 2026 model by Builes-Montaño and colleagues in Diabetes Therapy found these pairs gave similar average weight loss in type 2 diabetes:
Semaglutide 2.4 mg and tirzepatide 10 mg (99.4% probability of a match)
Semaglutide 7.2 mg and tirzepatide 15 mg (94.8% probability of a match)
Lower semaglutide doses did not match higher tirzepatide doses
Disclaimer: these pairs come from a computer model of group averages, not from a drug label or a switching trial, and two of its three authors work for the maker of semaglutide. They are shown to report the study. They are not a conversion chart and not a dose for anyone.
Sources: Builes-Montaño CE and others, "Dose-Response and Clinical Equivalence of Semaglutide and Tirzepatide for Weight Loss in Type 2 Diabetes: A Model-Based Analysis." Diabetes Therapy, 2026. PMID 42252377; Kurinami N, Takada M and others, "Early Dose Escalation of Tirzepatide after Switching from Semaglutide in Type 2 Diabetes Mellitus." Endocrinology and Metabolism, 2025. PMC12765867, PMID 41088952; Lahey AM and others, insulin needs over six months after a move to tirzepatide, Pharmacotherapy, 2025. PMID 40108854; OZEMPIC (semaglutide) injection, US prescribing information, Novo Nordisk, DailyMed version of June 2026; ZEPBOUND (tirzepatide) injection, US prescribing information, Eli Lilly, revised 08/2026, DailyMed
The dose steps in each label
Both drugs start low and climb in 4-week steps, to cut stomach side effects. Wegovy and Zepbound are labelled for weight loss, among other uses. Ozempic and Mounjaro are labelled for type 2 diabetes. We laid the four schedules side by side with a script, at the fastest pace each label allows up to its main maintenance dose. The later Wegovy 7.2 mg step is listed under the table.
The current US labels for the weekly shots list these steps, each held at least 4 weeks:
| Weeks on the drug | Wegovy | Ozempic | Mounjaro and Zepbound |
|---|---|---|---|
| 1 to 4 | 0.25 mg | 0.25 mg | 2.5 mg |
| 5 to 8 | 0.5 mg | 0.5 mg | 5 mg |
| 9 to 12 | 1 mg | 1 mg | 7.5 mg |
| 13 to 16 | 1.7 mg | 2 mg | 10 mg |
| 17 to 20 | 2.4 mg | 2 mg | 12.5 mg |
| 21 onward | 2.4 mg | 2 mg | 15 mg |
Disclaimer: this is the fastest pace the US labels give to each main maintenance dose, shown to report the labels. The labels set these steps and let a prescriber delay a step if side effects occur. It is not a plan for you.
The same four US labels add these points about the upper steps:
Wegovy: may go to 7.2 mg for weight in adults once 2.4 mg has been held for 4 weeks or more
Zepbound: kept at 5, 10 or 15 mg; the 2.5 mg start is not a keeping dose
Ozempic and Mounjaro: move up only if blood sugar needs it
Disclaimer: these notes are quoted from the labels to show where each schedule can stop or go further. They are not a target dose and not a plan for anyone.
Sources: WEGOVY (semaglutide) injection and tablets, US prescribing information, Novo Nordisk, revised 06/2026, DailyMed; OZEMPIC (semaglutide) injection, US prescribing information, Novo Nordisk, DailyMed version of June 2026; MOUNJARO (tirzepatide) injection, US prescribing information, Eli Lilly, DailyMed version of August 2026; ZEPBOUND (tirzepatide) injection, US prescribing information, Eli Lilly, revised 08/2026, DailyMed
Timing: how long each drug stays in the body
Timing is where the labels help most. The Ozempic label puts the half-life of semaglutide at about one week. It adds that the drug stays in the blood for about five weeks after the last dose. The tirzepatide labels give a half-life of about five days.
So after a last semaglutide shot, it stays in the blood for about five weeks, per the label. That matters because the Wegovy label advises against using it with any other GLP-1 drug. The Zepbound label says the same in reverse. The labels do not say how long to wait between them. None of the three switching studies we checked reported the gap it used: we read the Kurinami and Barakat papers in full and the Jabbour abstract.
The labels set these windows for a missed weekly dose, which show how each drug treats a gap:
Ozempic: give within 5 days of the missed dose, or skip it
Mounjaro and Zepbound: give within 4 days (96 hours), or skip it
Wegovy: after 2 or more missed doses in a row, restart the steps lower down
Disclaimer: these are missed-dose rules for each drug on its own, quoted from the labels. None of them is a rule for switching between drugs, and none is advice on timing a switch.
Sources: OZEMPIC (semaglutide) injection, US prescribing information, Novo Nordisk, DailyMed version of June 2026; MOUNJARO (tirzepatide) injection, US prescribing information, Eli Lilly, DailyMed version of August 2026; ZEPBOUND (tirzepatide) injection, US prescribing information, Eli Lilly, revised 08/2026, DailyMed; WEGOVY (semaglutide) injection and tablets, US prescribing information, Novo Nordisk, revised 06/2026, DailyMed; Kurinami N, Takada M and others, "Early Dose Escalation of Tirzepatide after Switching from Semaglutide in Type 2 Diabetes Mellitus." Endocrinology and Metabolism, 2025. PMC12765867, PMID 41088952; Jabbour S and others, prospective 12-week study of a direct switch from GLP-1 drugs to tirzepatide, Endocrine Practice, 2024. PMID 38723893; Barakat S, Ramdeen S and Khaimova R, "Safety and Efficacy of Switching Patients With Type 2 Diabetes From Glucagon-Like Peptide-1 Receptor Agonists to Tirzepatide: A Case Series." Hospital Pharmacy, 2024. PMC11497530, PMID 39449861
What the published switching studies did
Three studies we found followed real people through the switch. All three were in type 2 diabetes, and all are small. A separate computer model ran the switch on paper.
The 2025 Kurinami study in Endocrinology and Metabolism followed 15 Japanese adults who moved from Ozempic to Mounjaro after losing less than 3% of their weight:
Before: semaglutide 1.0 mg weekly
Tirzepatide: 2.5 mg for 4 weeks, then 5 mg for 4 weeks
Then 7.5 mg (10 people) or 7.5 mg for 4 weeks and on to 10 mg (5 people)
Disclaimer: this reports what one clinic did in a retrospective study, without a comparison group. It is not a switch plan. Neither group's weight change was statistically significant at 3 months.
The 2024 Jabbour study in Endocrine Practice, with Eli Lilly authors, moved adults with type 2 diabetes straight from a stable GLP-1 drug:
Before: liraglutide, semaglutide (0.5, 1.0 or 2.0 mg) or dulaglutide, for at least 3 months
Tirzepatide: started directly at 5 mg, skipping the 2.5 mg step
Disclaimer: this reports the design of one 12-week study with authors from the drug maker. It is not a recommendation to skip a step, and the label start remains 2.5 mg.
In the Kurinami study, no one reported stomach side effects while moving up, and no one stopped. The authors think this was because everyone had already handled semaglutide. In the Jabbour study, 13.2% had stomach side effects over 12 weeks and 2% stopped the drug for side effects. Blood sugar and weight both improved on average.
A Lilly computer model also ran the switch on paper, from semaglutide or dulaglutide to tirzepatide. It predicted more drops in blood sugar and weight, even at the lowest keeping dose. That is a forecast from trial data, not a measured result in people who switched.
The third study is a 2024 case series in Hospital Pharmacy. It looked back at 10 adults in one US health system. Four came from semaglutide and six from dulaglutide. The clinic used its own table to match each old dose to a first tirzepatide dose. At 3 months, A1C fell by 0.7 points on average in the 8 people with data. The authors reported few side effects; one person had possible acute gallbladder inflammation (cholecystitis) that the authors tied to tirzepatide. One author owns stock in Eli Lilly.
Sources: Kurinami N, Takada M and others, "Early Dose Escalation of Tirzepatide after Switching from Semaglutide in Type 2 Diabetes Mellitus." Endocrinology and Metabolism, 2025. PMC12765867, PMID 41088952; Jabbour S and others, prospective 12-week study of a direct switch from GLP-1 drugs to tirzepatide, Endocrine Practice, 2024. PMID 38723893; Urva S and others, "Model-based simulation of glycaemic effect and body weight loss when switching from semaglutide or dulaglutide to once weekly tirzepatide." Current Medical Research and Opinion, 2024. PMID 38407177; Barakat S, Ramdeen S and Khaimova R, "Safety and Efficacy of Switching Patients With Type 2 Diabetes From Glucagon-Like Peptide-1 Receptor Agonists to Tirzepatide: A Case Series." Hospital Pharmacy, 2024. PMC11497530, PMID 39449861
Our timing table: label pace vs the two studies
The first study calls itself early dose escalation, so we checked how early it really was. Our script lines up the week each tirzepatide dose was first given: at the label's fastest pace, in the Kurinami study, and in the Jabbour study.
Week of tirzepatide treatment when each dose was first given, from the Mounjaro and Zepbound labels and the two studies:
| Tirzepatide dose | Label fastest pace | Kurinami 2025 | Jabbour 2024 |
|---|---|---|---|
| 5 mg | Week 5 | Week 5 | Week 1 |
| 7.5 mg | Week 9 | Week 9 | Not part of the study |
| 10 mg | Week 13 | Week 13 | Not part of the study |
Disclaimer: this compares published schedules to show how they differ. It is not advice to move faster or slower, and the right pace for any one person is a prescriber's decision.
The result surprised us. The Kurinami clinic moved at exactly the label's fastest pace. Its "early" part was going on to a higher step instead of stopping lower, not moving faster. Only the Jabbour study cut time, by skipping the first 4-week step.
Sources: MOUNJARO (tirzepatide) injection, US prescribing information, Eli Lilly, DailyMed version of August 2026; ZEPBOUND (tirzepatide) injection, US prescribing information, Eli Lilly, revised 08/2026, DailyMed; Kurinami N, Takada M and others, "Early Dose Escalation of Tirzepatide after Switching from Semaglutide in Type 2 Diabetes Mellitus." Endocrinology and Metabolism, 2025. PMC12765867, PMID 41088952; Jabbour S and others, prospective 12-week study of a direct switch from GLP-1 drugs to tirzepatide, Endocrine Practice, 2024. PMID 38723893
Label notes people miss when switching
- Birth control pills: the Mounjaro and Zepbound labels advise anyone on the pill to use a non-oral method, or add a barrier method. That holds for 4 weeks after starting and after each step up. The semaglutide labels we read carry no such advice.
- Insulin: a study followed 66 people on insulin who moved from a GLP-1 drug to tirzepatide. Their insulin needs fell over 6 months. Eight of them had low blood sugar.
- Other medicines: a 2026 case report describes lithium poisoning in one man days after he changed from semaglutide to tirzepatide. The authors call for closer lithium checks around any such change.
These are reasons a switch belongs with a prescriber who can see all of a person's medicines. They are not instructions to change any of them.
Sources: MOUNJARO (tirzepatide) injection, US prescribing information, Eli Lilly, DailyMed version of August 2026; ZEPBOUND (tirzepatide) injection, US prescribing information, Eli Lilly, revised 08/2026, DailyMed; Lahey AM and others, insulin needs over six months after a move to tirzepatide, Pharmacotherapy, 2025. PMID 40108854; Burson JR and Leung JG, "Lithium toxicity following a change from semaglutide to tirzepatide for weight loss management." Mental Health Clinician, 2026. PMID 41646202
What the top pages for this search say
Most results for this search are telehealth and clinic pages. On 23 October 2026 we read the eight that rank besides the study itself. Five could be read as text. A script counted what our saved copies contain:
| What we checked | Pages |
|---|---|
| Linked an official drug label or product information | 2 of 5 |
| Said there is no official milligram match between the two drugs | 2 of 5 |
| Named a published switching study | 1 of 5 |
| Said how long semaglutide stays in the body | 1 of 5 |
| Mentioned the tirzepatide label note on birth control pills | 0 of 5 |
So the label facts that bear most on timing, the five-week tail and the pill note, were the least likely to show up. It is one day's look at one search, not a full survey.
Sources: Top US results for "switch from semaglutide to tirzepatide", read by us on 23 October 2026
Common questions
Is a milligram of semaglutide the same as a milligram of tirzepatide?+
No. They are different drugs with different dose scales, and none of the four US labels gives a conversion between them. A 2026 modelling study matched certain dose pairs for average weight loss, set out with its figures in the dose section above, but it was a statistical model, not a label rule, and two of its authors work for the maker of semaglutide.
How long after semaglutide can I take tirzepatide?+
No label sets a gap for this switch. The Wegovy and Zepbound labels both say not to use them with another GLP-1 drug, and the Ozempic label says semaglutide stays in the blood for about five weeks after the last shot. The three switching studies we read, by Kurinami, Jabbour and Barakat, did not report one. The timing is a decision for the prescriber.
Can I switch back and forth between semaglutide and tirzepatide?+
None of the three switching studies we read (Kurinami 2025, Jabbour 2024 and the Barakat 2024 case series) tested repeated switching. What the labels do say is that a long break changes the plan: the Wegovy label says that after two or more missed doses in a row, the dose steps start again lower down. Each switch is a new start that a prescriber should plan.
What is the route of administration for tirzepatide?+
Mounjaro and Zepbound are injected under the skin once a week, in the stomach area, the thigh, or the back of the upper arm when someone else gives it. The labels say to change the spot each week. Both come in pens and vials.
How much weight do people lose after switching?+
The studies are small and short. In the Japanese study of 15 people, weight fell in both dose groups over three months, but neither change reached statistical significance. The 12-week study with Lilly authors reported a modest extra weight loss on average. No study gives a number anyone can expect for themselves.
Sources: Builes-Montaño CE and others, "Dose-Response and Clinical Equivalence of Semaglutide and Tirzepatide for Weight Loss in Type 2 Diabetes: A Model-Based Analysis." Diabetes Therapy, 2026. PMID 42252377; OZEMPIC (semaglutide) injection, US prescribing information, Novo Nordisk, DailyMed version of June 2026; WEGOVY (semaglutide) injection and tablets, US prescribing information, Novo Nordisk, revised 06/2026, DailyMed; ZEPBOUND (tirzepatide) injection, US prescribing information, Eli Lilly, revised 08/2026, DailyMed; MOUNJARO (tirzepatide) injection, US prescribing information, Eli Lilly, DailyMed version of August 2026; Kurinami N, Takada M and others, "Early Dose Escalation of Tirzepatide after Switching from Semaglutide in Type 2 Diabetes Mellitus." Endocrinology and Metabolism, 2025. PMC12765867, PMID 41088952; Jabbour S and others, prospective 12-week study of a direct switch from GLP-1 drugs to tirzepatide, Endocrine Practice, 2024. PMID 38723893; Barakat S, Ramdeen S and Khaimova R, "Safety and Efficacy of Switching Patients With Type 2 Diabetes From Glucagon-Like Peptide-1 Receptor Agonists to Tirzepatide: A Case Series." Hospital Pharmacy, 2024. PMC11497530, PMID 39449861
Related pages
Tirzepatide vs Semaglutide
How the two compare in trials
Tirzepatide Dosage
The tirzepatide dose guide
Semaglutide Dosage Chart
Semaglutide steps in one chart
Is Zepbound the Same as Mounjaro?
One molecule, two labels
GLP-1 Side Effects
What the class can cause
Tirzepatide in Vietnam
Access and rules in Vietnam
This page reports what US drug labels and published studies say about moving from semaglutide to tirzepatide. It is background reading, not medical advice, and it is not a switch plan. Any change to these prescription drugs belongs with the prescriber who knows your health and your other medicines.